TLR9 and hepatocellular carcinoma: Specifically, inhibition of mtDNA-induced TLR9 pathway enhanced the therapeutic effect of sorafenib in HCC, and this would be particularly important to allow targeting of the mtDNA-TLR9 pathway as a therapeutic intervention strategy.